EMEA-002945-PIP01-20
Key facts
| Active substance |
anti-CD40L humanized monoclonal antibody (SAR441344)
|
| Therapeutic area |
Immunology-Rheumatology-Transplantation
|
| Decision number |
P/0200/2021
|
| PIP number |
EMEA-002945-PIP01-20
|
| Pharmaceutical form(s) |
Solution for injection
|
| Condition(s) / indication(s) |
Treatment of Sjogren's Syndrome
|
| Route(s) of administration |
|
| Contact for public enquiries |
Sanofi-aventis recherche & développement
E-mail: contact-us@sanofi.com |
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|